After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Vertex Pharmaceuticals, Inc. (VRTX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.40, or -0.09%, to $433.00. The Vertex Pharmaceuticals, Inc. has recorded 36,669 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Vertex Pharmaceuticals, Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $433.40 and fluctuated between $434.85 as its day high and $431.14 as its day low. The current market capitalization of Vertex Pharmaceuticals, Inc. is $111.68B. A total of 1.18 million shares were traded on the day, compared to an average of 1.45M shares.
Insider Activity
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, VRTX has seen 1 BUY and 9 SELL insider trades, representing the acquisition of 11,250 and the disposition of 46,558 shares. Over the last 12 months, there were 50 BUYs and 217 SELLs from insiders. Insiders purchased 457,421 shares during that period but sold 434,593.
In the most recent transaction, LEIDEN JEFFREY M sold 6,648 shares of VRTX for 419.07 per share on Jan 08. After the transaction, the Executive Chairman now owns 2,423 company shares. In a previous transaction on Jan 02, WAGNER CHARLES F JR sold 3,000 shares at 405.00 per share. VRTX shares that EVP & Chief Financial Officer owns now total 43,693.
Among the insiders who sold shares, Kewalramani Reshma disposed of 17,135 shares on Dec 15 at a per-share price of $407.00. This resulted in the CEO & President holding 108,711 shares of VRTX after the transaction. In another insider transaction, LEIDEN JEFFREY M sold 13,354 shares at $399.42 per share on Dec 13. Company shares held by the Executive Chairman now total 9,071.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for VRTX in the last 3 months, the mean price target is $417.96 with high estimates of $500.00 and low estimates of $325.00. In terms of 52-week highs and lows, VRTX has a high of $431.10 and a low of $283.60.
As of this writing, VRTX has an earnings estimate of $4.07 per share for the current quarter. EPS was calculated based on a consensus of 20 estimates, with a high estimate of $4.43 per share and a lower estimate of $3.54. The company reported an EPS of $3.89 in the last quarter, which was 0.30% higher than expectations of $3.88.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. VRTX’s latest balance sheet shows that the firm has $7.52B in Cash & Short Term Investments as of fiscal 2021. There were $967.40M in debt and $2.14B in liabilities at the time. Its Book Value Per Share was $64.05, while its Total Shareholder’s Equity was $10.10B.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRTX is Buy with a score of 4.38.
